iPSC line to identify novel therapies for ARVC

Technology

Duke inventors have developed a novel induced pluripotent stem cell (iPSC) line that contains a mutation that impacts the TAX1BP3 gene, which causes arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC). Specifically, the iPSCs were derived from mononuclear cells taken from an ARVC patient with a known mutation in the TAX1BP3 gene.

Applications

• Identify compounds that can correct this mutation
• Test novel therapies for ARVC such as Wnt activators